Apyx Medical (NASDAQ:APYX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Apyx Medical Corporation is an energy technology company. It provides products in the cosmetic and surgical markets. The company’s Helium Plasma Technology is marketed and sold as Renuvion(R) in the cosmetic surgery market and J-Plasma(R) in the hospital surgical market. Apyx Medical Corporation, formerly known as Bovie Medical Corporation, is based in FL, United States. “

Separately, ValuEngine lowered shares of Apyx Medical from a “strong-buy” rating to a “buy” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $7.94.

Shares of NASDAQ APYX traded up $0.02 during midday trading on Monday, reaching $6.77. The company’s stock had a trading volume of 66,304 shares, compared to its average volume of 229,085. The company has a current ratio of 10.38, a quick ratio of 9.57 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $6.98 and a 200 day moving average price of $6.30. Apyx Medical has a one year low of $3.55 and a one year high of $8.89. The company has a market cap of $234.06 million, a price-to-earnings ratio of -23.34 and a beta of 0.09.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Apyx Medical had a net margin of 255.57% and a negative return on equity of 14.88%. The business had revenue of $6.57 million for the quarter, compared to the consensus estimate of $5.85 million. During the same period in the previous year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 78.0% on a year-over-year basis. Research analysts anticipate that Apyx Medical will post -0.66 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in APYX. Advisory Services Network LLC grew its position in Apyx Medical by 66.7% in the second quarter. Advisory Services Network LLC now owns 5,000 shares of the company’s stock worth $34,000 after acquiring an additional 2,000 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Apyx Medical by 277.9% during the 2nd quarter. Bank of Montreal Can now owns 3,779 shares of the company’s stock worth $26,000 after buying an additional 2,779 shares during the period. Bailard Inc. boosted its holdings in shares of Apyx Medical by 20.4% during the 2nd quarter. Bailard Inc. now owns 18,922 shares of the company’s stock worth $127,000 after buying an additional 3,200 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Apyx Medical during the 2nd quarter worth $79,000. Finally, Stone Ridge Asset Management LLC bought a new stake in shares of Apyx Medical during the 2nd quarter worth $87,000. Institutional investors and hedge funds own 51.06% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Further Reading: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Apyx Medical (APYX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.